Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020192665 - NUCLEOSIDE DERIVATIVE FOR PREVENTING AND TREATING INFLAMMATION AND APPLICATION THEREOF

Publication Number WO/2020/192665
Publication Date 01.10.2020
International Application No. PCT/CN2020/080993
International Filing Date 25.03.2020
IPC
C07D 473/10 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
473Heterocyclic compounds containing purine ring systems
02with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6
04two oxygen atoms
06with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
10with methyl radicals in positions 3 and 7, e.g. theobromine
C07D 473/08 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
473Heterocyclic compounds containing purine ring systems
02with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6
04two oxygen atoms
06with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
08with methyl radicals in positions 1 and 3, e.g. theophylline
C07D 473/06 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
473Heterocyclic compounds containing purine ring systems
02with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6
04two oxygen atoms
06with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
C07D 473/02 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
473Heterocyclic compounds containing purine ring systems
02with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6
C07D 239/553 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
239Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
02not condensed with other rings
24having three or more double bonds between ring members or between ring members and non-ring members
28with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
46Two or more oxygen, sulfur or nitrogen atoms
52Two oxygen atoms
54as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
545with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
553with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
A61P 29/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs)
Applicants
  • 四川大学华西医院 WEST CHINA HOSPITAL OF SICHUAN UNIVERSITY [CN]/[CN]
Inventors
  • 黄文 HUANG, Wen
Agents
  • 成都科海专利事务有限责任公司 CHENGDU KEHAI PATENT AFFAIRS CO., LTD.
Priority Data
201910239233.X27.03.2019CN
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) NUCLEOSIDE DERIVATIVE FOR PREVENTING AND TREATING INFLAMMATION AND APPLICATION THEREOF
(FR) DÉRIVÉ NUCLÉOSIDIQUE DESTINÉ À LA PRÉVENTION ET AU TRAITEMENT D'UNE INFLAMMATION ET SON UTILISATION
(ZH) 防治炎症反应的核苷类衍生物及其应用
Abstract
(EN)
The present invention provides a nucleoside derivative for preventing and treating inflammation and an application thereof in the preparation of a drug for preventing and treating inflammatory diseases. The nucleoside derivative for preventing and treating inflammation provided by the present invention can significantly ameliorate conditions such as pancreatitis, hepatitis, and arthritis, ameliorate organ damage and inflammatory indexes, and have better effects than positive control drug, indomethacin. Compared with conventional anti-inflammatory drugs, aspirin, ibuprofen, indomethacin, phenylbutazone, diclofenac, piroxicam, and glucocorticoids, the nucleoside derivative for preventing and treating inflammation provided by the present invention has the advantage of significantly fewer side effects.
(FR)
La présente invention concerne un dérivé nucléosidique destiné à la prévention et le traitement d'une inflammation et son utilisation dans la préparation d'un médicament pour la prévention et le traitement de maladies inflammatoires. Le dérivé nucléosidique pour la prévention et le traitement d'une inflammation selon la présente invention peut soulager de manière significative des états pathologiques tels que la pancréatite, l'hépatite et l'arthrite, soulager des lésions d'organe et des indices inflammatoires, et permet d'avoir de meilleurs effets qu'un médicament témoin positif, l'indométacine. Le dérivé nucléosidique pour la prévention et le traitement de l'inflammation fourni par la présente invention a l'avantage d'avoir beaucoup moins d'effets secondaires, par comparaison avec des médicaments anti-inflammatoires classiques, l'aspirine, l'ibuprofène, l'indométacine, la phénylalanine, le diclofénac, le piroxicam et des glucocorticoïdes.
(ZH)
本发明提供了一类防治炎症反应的核苷类衍生物,以及该衍生物在制备防治炎症疾病的药物中的应用。本发明提供的防治炎症反应的核苷类衍生物能够明显改善胰腺炎、肝炎、关节炎等病情,改善器官受损和炎性指标,效果优于阳性对照药吲哚美辛。相比于传统抗炎药物阿司匹林、布洛芬、吲哚美辛、保泰松、双氯芬酸、吡罗昔康以及糖皮质激素,本发明提供的防治炎症反应的核苷类衍生物具有副作用明显更小的优势。
Also published as
Latest bibliographic data on file with the International Bureau